Merck announced today that it has launched a phase 3 clinical trial evaluating its ' MK-1084 ' in combination with Keytruda for the first-line treatment of selected patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor ' KRAS G12C ' mutations and express ' PD-L1 '.

KRAS is one of the most common cancer mutations, and KRAS G12C is the most common KRAS mutation in NSCLC patients," said Dr. Marjorie Green, Senior Vice President and Head of Global Oncology and Clinical Development at Merck Research Laboratories.

Merck has launched a Phase 3, randomized, double-blind, multicenter clinical trial (NCT06345729) evaluating MK-1084 once-daily + Keytruda administered once every three weeks, versus Keytruda + placebo.

The study's primary endpoints are progression-free survival and overall survival, and key secondary endpoints include objective response rate and duration of response.


Copyright (c) 2024 CercleFinance.com. All rights reserved.